I know I'll get persecuted on this as well, but I'
Post# of 153887
(Total Views: 1102)
Posted On: 04/13/2021 2:48:39 PM
I know I'll get persecuted on this as well, but I'm siding with you on this one. I don't subscribe to the BP, FDA, shorts, market maker conspiracies. I like the drug, and I like NPs fiery attitude, but for the stock to go up we need some better execution. The factual records(at least since I've been a shareholder Feb 2019).
- 2018 prostagene acquisition that led to a useless prostrate cancer test and CMO firing(millions off wasted dollars/shares).
- tnbc first injection aug 2019...how many enrollees in that trial? The basket trial hasn't been around as long and has more patients
- premature BTD attempt early 2020
- first part of rolling BLA submission marchish 2019...the rest april 2020...rejected needs refiling... timeline??
- covid trial M/m not good enough for EUA, phase 3 could be done for moderate but focus on critical
- phase 3 critical enrollment stalled at mid point, dsmc recommendation, enrollment expedited
- results not near as good as hoping (dosing issue?) Need another trial to prove theory
- gvhd on long hold
- hiv BLA in limbo needs sorting issues out
- pre btd cancer hopeful (results looking good not sure if we have enough patients for FDA TBD)
- nash hopeful but unproven
- long haulers phase 2 hopeful
So we have some hopefuls and some missteps along the way. Investors need confidence that revenue can be had. You could look at Brazil and philippines...but what about mexico... nothing. Remember the longen(sp?) China? Nothing. So the track record of completing anything from the many different squirrels we've been chasing isn't great and vyera isn't exactly a household name. I'd say we're currently lucky to be where the share price is right now until revenue is delivered by someone. Until then the risk averse will invest else where and the day traders will buy on PR runups and sell for small daily profits.
This is not a bash post this is factual events listed from the companies history to where we are now. We have a good drug we can't sell...so we wait. Sometimes it feels like one step forward, two steps back, but I know that the current c suite team of kelly, Nader and recknor are emotionally invested in this drug and what it can do, so I know they'll keep going. Hopefully learning from the past as they go.
- 2018 prostagene acquisition that led to a useless prostrate cancer test and CMO firing(millions off wasted dollars/shares).
- tnbc first injection aug 2019...how many enrollees in that trial? The basket trial hasn't been around as long and has more patients
- premature BTD attempt early 2020
- first part of rolling BLA submission marchish 2019...the rest april 2020...rejected needs refiling... timeline??
- covid trial M/m not good enough for EUA, phase 3 could be done for moderate but focus on critical
- phase 3 critical enrollment stalled at mid point, dsmc recommendation, enrollment expedited
- results not near as good as hoping (dosing issue?) Need another trial to prove theory
- gvhd on long hold
- hiv BLA in limbo needs sorting issues out
- pre btd cancer hopeful (results looking good not sure if we have enough patients for FDA TBD)
- nash hopeful but unproven
- long haulers phase 2 hopeful
So we have some hopefuls and some missteps along the way. Investors need confidence that revenue can be had. You could look at Brazil and philippines...but what about mexico... nothing. Remember the longen(sp?) China? Nothing. So the track record of completing anything from the many different squirrels we've been chasing isn't great and vyera isn't exactly a household name. I'd say we're currently lucky to be where the share price is right now until revenue is delivered by someone. Until then the risk averse will invest else where and the day traders will buy on PR runups and sell for small daily profits.
This is not a bash post this is factual events listed from the companies history to where we are now. We have a good drug we can't sell...so we wait. Sometimes it feels like one step forward, two steps back, but I know that the current c suite team of kelly, Nader and recknor are emotionally invested in this drug and what it can do, so I know they'll keep going. Hopefully learning from the past as they go.
(23)
(0)